At the recent 2026 10th Everything Grows Conference, Hangzhou DIAGENS Biotechnology Co., Ltd. presented its self-developed iMedImage® medical imaging base model in the "Hangzhou AI 18 Arhats" joint exhibition area.
DIAGENS-B was listed on the Main Board of the Hong Kong Stock Exchange on March 30, becoming the first publicly traded company focused on large-scale medical imaging models. As the first listed enterprise among the "Hangzhou AI 18 Arhats," its public offering stage saw an oversubscription of 1,073 times, and it currently holds a market capitalization exceeding HKD 25 billion.
At the exhibition, the company highlighted two core products: its independently developed iMedImage® medical imaging base model and the AI AutoVision® chromosome karyotyping auxiliary diagnosis software built upon it. According to on-site representatives, iMedImage® supports 19 medical imaging modalities, including chromosome imaging, CT, MRI, ultrasound, and pathology, covering over 90% of clinical medical imaging scenarios. Its disruptive value lies in its technology path of pre-training plus lightweight fine-tuning, which can reduce the development cost of specialized disease AI models by over 90%, fundamentally breaking the long-standing cost and efficiency bottlenecks that have hindered the large-scale adoption of AI in healthcare.
The AI AutoVision® product, developed based on this foundational model, enables fully automated chromosome segmentation, counting, and case-level anomaly detection. It compresses the traditionally highly manual, weeks-long chromosome karyotyping analysis process down to just 2.5 minutes per image, with an overall accuracy rate exceeding 99%. Market data indicates that DIAGENS-B holds the leading market share in the field of chromosome karyotype analysis in China, breaking the long-term monopoly previously held by international manufacturers.
DIAGENS-B founder, chairman, and general manager Song Ning stated, "DIAGENS will continue to deepen its innovation in underlying AI medical imaging technology, empowering accessible healthcare with robust technology and contributing to Hangzhou's goal of becoming the nation's leading city for artificial intelligence innovation and development."